Atrial Fibrillation

Atrial Fibrillation

Atrial Fibrillation panel [46 genes]: the panel includes genes with clinical and functional evidence of association with familial atrial fibrillation. Many of the included genes are associated with defined electrophysiological phenotypes or even structural heart diseases in which the development of atrial fibrillation may be the first or the main manifestation of the disease.

Informed consent
ACTC1EMDGATA4GJA5GNB2HCN4IRX3KCNA5KCND3KCNE1
KCNE2KCNE3KCNE5KCNJ2KCNQ1LMNANKX2-5NKX2-6NPPAPITX2
RYR2SCN1BSCN2BSCN4BSCN5ATBX5TTRABCC9*CACNB2*GATA5*
GATA6*GJA1*GREM2*JPH2*KCND2*KCNH2*KCNJ5*KCNJ8*KCNK3*MYBPHL*
SCN3B*TNNI3*TNNI3K*TNNT2*TPM1*ZFHX3*

Arrhythmias general panel [251 genes]: this panel is mainly aimed at the diagnosis of cases where it is not possible to establish a clearly defined phenotype, but where cardiac arrhythmias are the main manifestation.

It is mainly intended for subjects with personal or familial history of sudden death with unknown origin or subjects with ventricular fibrillation of unknown origin that meet the above-mentioned characteristics.

Study requisition form
Informed consent

Cardiovascular diseases global panel [405 genes]: this panel includes all genes associated or potentially associated with the development of inherited cardiovascular diseases as well as genes associated with increased global/general cardiovascular risk.

It covers a group of heterogeneous diseases, and genetic testing allows for the differential diagnosis between them. It is also useful when a multigenic etiology is suspected.

It should be considered when an exhaustive study of all genes related to cardiovascular pathologies is intended, especially in cases of sudden death where clinical or pathological information is incomplete or the diagnosis is unclear.

As for research, it is an attractive alternative to the exomes because it includes both genes with proven pathogenicity and candidate genes. The study ensures maximum yield with adequate coverages (which allows for assessing structural variants, such as large deletions and duplications).

Study requisition form
Informed consent

The panel includes genes with clinical and functional evidence of association with familial atrial fibrillation. Many of the included genes are associated with defined electrophysiological phenotypes or even structural heart diseases in which the development of atrial fibrillation may be the first or the main manifestation of the disease.

Informed consent
ACTC1EMDGATA4GJA5
GNB2HCN4IRX3KCNA5
KCND3KCNE1KCNE2KCNE3
KCNE5KCNJ2KCNQ1LMNA
NKX2-5NKX2-6NPPAPITX2
RYR2SCN1BSCN2BSCN4B
SCN5ATBX5TTRABCC9*
CACNB2*GATA5*GATA6*GJA1*
GREM2*JPH2*KCND2*KCNH2*
KCNJ5*KCNJ8*KCNK3*MYBPHL*
SCN3B*TNNI3*TNNI3K*TNNT2*
TPM1*ZFHX3*

This panel is mainly aimed at the diagnosis of cases where it is not possible to establish a clearly defined phenotype, but where cardiac arrhythmias are the main manifestation.

It is mainly intended for subjects with personal or familial history of sudden death with unknown origin or subjects with ventricular fibrillation of unknown origin that meet the above-mentioned characteristics.

Study requisition form
Informed consent

This panel includes all genes associated or potentially associated with the development of inherited cardiovascular diseases as well as genes associated with increased global/general cardiovascular risk.

It covers a group of heterogeneous diseases, and genetic testing allows for the differential diagnosis between them. It is also useful when a multigenic etiology is suspected.

It should be considered when an exhaustive study of all genes related to cardiovascular pathologies is intended, especially in cases of sudden death where clinical or pathological information is incomplete or the diagnosis is unclear.

As for research, it is an attractive alternative to the exomes because it includes both genes with proven pathogenicity and candidate genes. The study ensures maximum yield with adequate coverages (which allows for assessing structural variants, such as large deletions and duplications).

Study requisition form
Informed consent
Nota genes
NOTES ON GENES
-> Priority genes: Genes where there is sufficient evidence (clinical and functional) to consider them as associated with the disease; they are included in clinical practice guidelines. -> Secondary genes: Genes related to the disease but with a lower level of evidence
or constituting sporadic cases. -> * Candidate genes: Without sufficient evidence in humans but potentially associated with the disease.
  • Patients with a family history of atrial fibrillation in the absence of predisposing factors such as hypertension, ischemic cardiomyopathy, structural or organic heart diseases.
  • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. January CT, et al. Circulation. 2014 Dec 2;130(23):2071-104.

The probability of finding a pathogenic mutation when a patient presents atrial fibrillation has not been clearly established. The yield could be higher in cases where there is a family history of this disorder, and when it occurs in young subjects without a clear cause.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

ACEPTAR
Aviso de cookies